5 Takeaways For Valeant Investors As Ackman Exits

Valeant Pharmaceuticals Intl Inc VRX fell to a new 52-week low of $10.50 after Bill Ackman sold his stake.

Pershing Square, the activist investor's firm, exited its 27.2 million share position at $11. Ackman will also step off the company's board.

David Maris of Wells Fargo reiterated his Underperform rating on the stock and the $11 sale price comes within his valuation range of $10-$13. Investors might consider Ackman’s exit as a sign Valeant may not see a major turnaround in the next several years.

“[W]e see this as a vote of no confidence for the stock and that things are continuing to go from bad to worse for Valeant,” Maris wrote in a note.

Maris said investors will take Pershing Square’s exit as a reflection that:

  • “The outlook is negative”
  • “The potential for meaningful near-term asset sales is unlikely”
  • “The legal proceedings/investigations may have greater risk than the Street is appreciating”
  • “A turnaround will take longer than expected or is not possible”
  • “The debt holders have an advantaged position in the capital structure, and as such the equity holders are at their mercy, especially in a bankruptcy situation.”

The analyst pointed out Valeant is in a challenging situation as it's set to launch an expensive-to-market drug into a crowded market with a worse-than-peers safety profile and weak core product trends.

The company is also burdened with several investigations and lawsuits and more than $29 billion of debt and obligations.

“We believe Valeant shares currently carry too much risk for us to be comfortable recommending them as an investment,” Maris added.

Related:

How Much Money Did Bill Ackman Lose In Valeant?

Pershing Square's Valeant Sale Sends 'Untimely Poor Signal'

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorReiterationAnalyst RatingsBill AckmanDavid MarisPershing SquareWells Fargo
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!